Patent Office issues EMED Notice of Allowance for a new patent

EL DORADO HILLS, Calif., Oct. 5, 2017 /PRNewswire/ -- EMED is pleased to announce that the USPTO issued a Notice of Allowance for a new patent that complements EMED's needle securement Intellectual Property portfolio. For additional information about our patented devices, contact us at [email protected].

We are very pleased to continue working to advance the standard of care in Primary Immunodeficiency therapy. Our innovative designs provide patients and clinicians with best-in-class devices that improve safety and patient satisfaction.

EMED pioneered the design of home infusion devices for SCIG and has since been working with clinicians to advance the standard of care in Primary Immunodeficiency. Our R&D activities focus on working with clinicians and patients to improve clinical protocols. Therapy optimization and safety translate into patient satisfaction which is paramount as Ig therapy continues to shift from hospitals to homes globally.

Needle securement technology is a growing requirement to ensure clinician and patient safety. EMED started developing needle safety technologies since the early 1990s and applied its proprietary designs to safety SCIG needle sets that resulted in a family of patents.

• A Notice of Allowance for the newest patent in the family, covering multiple aspects of its safety wing designs, was issued to EMED on September 28 of 2017.
• Formal issuance of the patent is expected in October of 2018.

VersaRate^®, a patent pending variable rate control set specifically designed for SCIG, was developed by EMED to provide patients with a way to adjust the infusion of Ig when therapy requires rate flow modifications.

• Issuance of a patent with claims covering the VersaRate is expected in early 2018.
• Originally invented and patent pending since 2011, VersaRate obtained FDA clearance in December of 2012 and European and Canadian authorization in April of 2013.

It is rewarding to see how our customers recognize innovation and our investment and efforts behind it. We appreciate how our pharmaceutical partners and global distributors recognize the benefits of our inventions and the value of our intellectual property. EMED will vigorously defend its IP against competitors who copy our devices without respect to patent laws.

"We are proud to continue innovating and improving clinical protocols. Our fundamental objective is to ensure customers and patients get best-in-class medical devices," said Paul Lambert, CEO of EMED Technologies Corporation.

EMED is fully committed to investing in the design and development of novel devices to improve the standard of care in infusion therapy. Our pipeline of infusion device platforms offers versatile options for the delivery of pharmaceuticals under specialized and proprietary delivery protocols.

To learn more about EMED visit our website at www.emedtc.com. 

SOURCE EMED Technologies Corporation